What are Gilead Sciences's total assets?

Gilead Sciences (GILD) holds $56.3B in total assets, down 0.3% year over year.

How much debt does Gilead Sciences have?

Gilead Sciences carries $22.2B in total debt against $23.5B of shareholders' equity, a debt-to-equity ratio of 0.94.

How much cash does Gilead Sciences have?

Gilead Sciences holds $7.6B in cash and equivalents.

Can Gilead Sciences cover its short-term obligations?

Its current ratio is 1.97 — current assets exceed current liabilities.

Where does Gilead Sciences's balance sheet data come from?

Every line is extracted from Gilead Sciences's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

Gilead Sciences GILD Balance Sheet Statement

Income Statement Balance Sheet Cash Flow Ratios Segments

Quarterly Annual TTM

YoY QoQ

Simplified Detailed

	TTM Q1 '26	TTM Q4 '25	TTM Q3 '25	TTM Q2 '25	TTM Q1 '25
Cash and cash equivalents	$7.63B-3.8%	$7.56B-24.3%	$7.33B+45.5%	$5.14B+85.6%	$7.93B+68.0%
Short-term investments	$15M—	——	——	——	——
Accounts receivable, net	$5.54B+5.5%	$5.9B+10.8%	$5.99B+9.7%	$5.62B+2.5%	$5.26B-4.8%
Inventories	$2.42B+20.1%	$2.59B+38.1%	$2.6B+66.2%	$2.09B+53.2%	$2.02B+33.6%
Raw materials	$1.36B+13.5%	$1.41B+9.2%	$1.4B+4.8%	$1.27B+1.0%	$1.2B-3.3%
Work in process	$1.28B+18.6%	$1.31B+54.2%	$1.34B+96.1%	$1.04B+29.4%	$1.08B+38.3%
Prepaid expenses and other current assets	$4.34B+53.5%	$4.02B+31.8%	$3.65B+10.9%	$2.9B+1.5%	$2.83B+1.0%
Total current assets	$18.64B+10.3%	$18.34B-4.3%	$17.87B+20.9%	$14.72B+19.5%	$16.9B+20.4%
Property and equipment, net	$5.64B+4.0%	$5.61B+3.5%	$5.5B+2.0%	$5.46B+2.1%	$5.42B+1.9%
Accumulated depreciation	$2.78B+9.5%	$2.7B+9.1%	$2.69B-81.1%	$2.62B-80.8%	$2.54B-80.5%
Goodwill	$8.31B0.0%	$8.31B0.0%	$8.31B0.0%	$8.31B0.0%	$8.31B0.0%
Deferred tax assets	$1.83B-41.6%	$2.36B-29.7%	$2.68B-36.5%	$2.88B-46.8%	$3.13B-52.6%
Total assets	$56.28B-0.3%	$59.02B0.0%	$58.53B+7.4%	$55.72B+4.0%	$56.43B+0.3%
Accounts payable	$645M-12.5%	$715M-14.2%	$808M-10.5%	$582M+8.4%	$737M+18.5%
Current portion of long-term debt	$1.31B-53.2%	$2.81B+54.7%	$2.81B+54.9%	$2.81B+55.1%	$2.81B-23.5%
Total current liabilities	$9.48B-23.2%	$11.81B-1.6%	$12.3B+4.9%	$11.19B+3.8%	$12.34B-5.2%
Long-term debt	$20.86B-5.8%	$22.13B-11.1%	$22.14B+3.3%	$22.14B+2.8%	$22.15B+2.9%
Other non-current liabilities	$1.2B-10.2%	$1.17B-10.0%	$1.18B-15.3%	$1.29B-9.0%	$1.34B-4.2%
Additional paid-in capital	$9.31B+14.3%	$8.93B+16.0%	$8.68B+18.4%	$8.37B+19.2%	$8.14B+19.4%
Retained earnings	$14.13B+29.3%	$13.73B+19.4%	$12.83B+15.8%	$11.33B+1.4%	$10.93B+2.6%
Accumulated other comprehensive income (loss)	$78M-15.2%	$39M-70.5%	$36M-50.7%	-$18M-119%	$92M+33.3%
Total stockholders' equity	$23.52B+22.7%	$22.7B+17.4%	$21.54B+16.6%	$19.67B+7.6%	$19.16B+9.3%
Total liabilities and stockholders' equity	$56.28B-0.3%	$59.02B0.0%	$58.53B+7.4%	$55.72B+4.0%	$56.43B+0.3%
Available-for-Sale Debt Securities - Amortized Cost (Due Within One Year)	——	——	——	——	——
AFS and Trading Securities - Unrealized Loss Position (<12 Months) Fair Value	——	——	——	——	——
AFS and Trading Securities - Unrealized Loss Position (<12 Months) Fair Value	——	——	——	——	——
Finished goods	$1.71B+13.3%	$1.65B+13.8%	$1.65B+16.3%	$1.6B+20.9%	$1.51B+11.7%
Short- term Investments	$15M—	——	——	——	——
Derivative Assets - Fair Value	$73M+65.9%	$56M-56.3%	$31M+343%	$7M-88.3%	$44M+12.8%
Deferred Tax Assets and Other Non-Current Assets	$4.55B+17.6%	$4.85B+28.5%	$4.87B-11.3%	$4.03B-15.5%	$3.87B-25.4%
Equity Securities (FV-NI and No Readily Determinable FV)	$8.83B+8.4%	$8.91B-17.4%	$8.34B+41.6%	$5.57B—	$8.14B—
Indefinite-Lived Intangible Assets	$2.3B-20.4%	$2.3B-20.4%	$2.7B-6.6%	$2.7B—	$2.89B—
Indefinite-Lived Intangible Assets, Gross	$2.3B-20.4%	$2.3B-20.4%	$2.7B-6.6%	$2.7B—	$2.89B—
Indefinite-Lived Research and Development Assets	$2.3B-20.4%	$2.3B-20.4%	$2.7B-6.6%	$2.7B—	$2.89B—
Indefinite-Lived Trademarks	$2.3B-20.4%	$2.3B-20.4%	$2.7B-6.6%	$2.7B—	$2.89B—
Deferred tax assets	$1.77B—	$1.96B—	$2B—	——	——
Intangible assets — net	$14.08B-14.5%	$14.68B-14.0%	$15.27B-13.5%	$15.87B-12.8%	$16.47B-12.4%
Other intangible assets—net	$16.38B-15.4%	$16.98B-14.9%	$17.97B-12.5%	$18.57B-18.7%	$19.36B-17.4%
Long- term Investments	$983M—	——	——	——	——
Other non-current assets	$4.55B+17.6%	$4.85B+28.5%	$4.87B-11.3%	$4.03B-15.5%	$3.87B-25.4%
Property, plant and equipment at cost	$8.42B—	$8.3B—	$8.19B—	——	——
Software and Technology Licenses, Net	$4.55B+17.6%	$4.85B+28.5%	$4.87B-11.3%	$4.03B-15.5%	$3.87B-25.4%
Accrued rebates	$4.12B-1.6%	$4.34B+11.4%	$4.93B+19.9%	$4.22B+7.4%	$4.19B-1.8%
Other accrued liabilities	$3.4B-26.3%	$3.95B-27.7%	$3.75B-23.4%	$3.59B-20.5%	$4.62B+3.4%
Derivative Liabilities - Fair Value	$24M-4.0%	$40M+1,233%	$29M+314%	$7M+250%	$25M+213%
Sales Discounts and Allowances	$98M+8.9%	$97M+9.0%	$97M+9.0%	$95M+3.3%	$90M-6.3%
Total debt	$22.17B-11.1%	$25.54B-6.5%	$24.94B+7.3%	$24.95B+6.8%	$24.95B-1.0%
AOCI - Foreign Currency Translation Adjustment, Net of Tax	$0—	$0—	$0—	$0—	$0—
Common stock; $0.001 par value; 6,000 shares authorized; 3,755 and 3,751 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively	$1M0.0%	$1M0.0%	$1M0.0%	$1M0.0%	$1M0.0%
Preferred stock; $0.001 par value; 100 shares authorized; no shares issued and outstanding	$0—	$0—	$0—	$0—	$0—
Aggregate Notional Principal Outstanding	$3.6B+5.9%	$3.9B+34.5%	$3.3B+43.5%	$3.7B+48.0%	$3.4B+70.0%
Cumulative Cost Basis	$8.42B—	$8.3B—	$8.19B—	——	——
Less: allowances for chargebacks	$661M-7.8%	$843M+11.1%	$762M+5.5%	$696M+3.6%	$717M+3.5%
Income taxes payable – long-term	$918M+12.1%	$896M+8.0%	$866M+10.7%	$859M+16.4%	$819M-58.4%
Allowance for doubtful accounts	$44M-25.4%	$41M-21.2%	$41M-36.9%	$50M-16.7%	$59M0.0%
Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax	$4M—	——	——	——	——
Gross Unrealized Gains	$1M—	——	——	——	——
Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year 5 Through 10	——	——	——	——	——
Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year 5 Through 10	——	——	——	——	——
Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year One Through Five	——	——	——	——	——
Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five	——	——	——	——	——
Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, Year One	——	——	——	——	——
Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One	——	——	——	——	——
Common stock, par value (in dollars per share)	$0.000.0%	$0.000.0%	$0.000.0%	$0.000.0%	$0.000.0%
Common stock, shares authorized (in shares)	5.6B0.0%	5.6B0.0%	5.6B0.0%	5.6B0.0%	5.6B0.0%
Common stock, shares issued (in shares)	1.2B-0.2%	1.2B-0.4%	1.2B-0.3%	1.2B-0.3%	1.2B-0.1%
Common Stock, Shares, Outstanding	1.2B-0.2%	1.2B-0.4%	1.2B-0.3%	1.2B-0.3%	1.2B-0.1%
Contract with Customer, Asset, after Allowance for Credit Loss	$589M+93.8%	$629M+127%	$695M+278%	$305M+84.8%	$304M+111%
Contract with Customer, Liability	$47M-16.1%	$48M-17.2%	$56M-17.6%	$58M-23.7%	$56M-33.3%
Short-term debt and current portion of long-term debt	$1.31B-53.2%	$2.81B+54.7%	$2.81B+54.9%	$2.81B+55.0%	$2.81B-23.5%
Debt Securities, Available-for-Sale, Amortized Cost, Excluding Accrued Interest, after Allowance for Credit Loss	$1B—	——	——	——	——
Less than 12 months	——	——	——	——	——
Estimated Fair Value	$997M—	——	——	——	——
Deferred income taxes	$392M-44.7%	$402M-44.5%	$597M-24.8%	$652M-28.1%	$709M-24.0%
Derivative Asset, Subject to Master Netting Arrangement, after Offset and Deduction	$49M—	——	——	——	——
Potential reduction in net position of total derivative assets	——	——	——	——	——
Derivative Liability, Subject to Master Netting Arrangement, after Offset and Deduction	$6M—	——	——	——	——
Potential reduction in net position of total derivative liabilities	$24M-4.0%	$40M+1,233%	$29M+314%	$7M+250%	$25M+213%
Notional	$3.6B+5.9%	$3.9B+34.5%	$3.3B+43.5%	$3.7B+48.0%	$3.4B+70.0%
Finite-Lived Intangible Assets, Accumulated Amortization	$17.78B+15.3%	$17.21B+16.1%	$16.61B+16.8%	$16.02B+17.5%	$15.42B+18.3%
Gross Carrying Amount	$31.86B-0.1%	$31.89B0.0%	$31.88B0.0%	$31.88B+0.2%	$31.88B+0.2%
Trademarks	$2.3B-20.4%	$2.3B-20.4%	$2.7B-6.6%	$2.7B—	$2.89B—
Indefinite- lived intangible impairment	$34.16B-1.8%	$34.19B-1.7%	$34.58B-0.5%	$34.58B-5.1%	$34.77B-4.6%
Inventory Net And Inventory Noncurrent	$4.34B+14.8%	$4.37B+21.7%	$4.39B+27.7%	$3.91B+15.5%	$3.78B+12.3%
Estimated litigation liability	$0—	$0—	$0—	——	——
Noncontrolling interests in subsidiaries	-$84M0.0%	-$84M0.0%	-$84M0.0%	-$84M0.0%	-$84M0.0%
Other long-term assets	$308M-14.2%	$393M+1.8%	$393M+2.9%	$369M—	$359M—
Preferred Stock, Par or Stated Value Per Share	$0.000.0%	$0.000.0%	$0.000.0%	$0.000.0%	$0.000.0%
Preferred Stock, Shares Authorized	5M0.0%	5M0.0%	5M0.0%	5M0.0%	5M0.0%
Preferred Stock, Shares Outstanding	0—	0—	0—	0—	0—
Severance accrual, current	——	——	——	——	——

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Ask your AI about Gilead Sciences.

Connect your AI assistant and get a quick read on the numbers, right in your chat.

Connect your AI

Claude

Questions, answered.

What are Gilead Sciences's total assets?: Gilead Sciences (GILD) holds $56.3B in total assets, down 0.3% year over year.
How much debt does Gilead Sciences have?: Gilead Sciences carries $22.2B in total debt against $23.5B of shareholders' equity, a debt-to-equity ratio of 0.94.
How much cash does Gilead Sciences have?: Gilead Sciences holds $7.6B in cash and equivalents.
Can Gilead Sciences cover its short-term obligations?: Its current ratio is 1.97 — current assets exceed current liabilities.
Where does Gilead Sciences's balance sheet data come from?: Every line is extracted from Gilead Sciences's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.